U.S. Markets closed

Is Avinger (AVGR) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research

Investors focused on the Medical space have likely heard of Avinger (AVGR), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Avinger is one of 844 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AVGR is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for AVGR's full-year earnings has moved 58.76% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that AVGR has returned about 56.67% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.57%. This shows that Avinger is outperforming its peers so far this year.

Looking more specifically, AVGR belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #105 in the Zacks Industry Rank. Stocks in this group have gained about 6.55% so far this year, so AVGR is performing better this group in terms of year-to-date returns.

AVGR will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Avinger, Inc. (AVGR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research